Please note: Sessions are run on the Zoom Webinar platform (which automatically launches when you click View Session) and all sessions are run in EDT Timezone and will be available on-demand on July 13th


Track Name Speakers
8:50 AM - 9:00 AM (EDT)
OCTSKEYNOTE: Next Generation for Cell TherapiesCarl June - Perelman School of Medicine, University of Pennsylvania
9:05 AM - 9:45 AM (EDT)
OCTSEXECUTIVE PANEL: Exploring the hurdles that are in place whilst targeting solid tumors; and how to clear the route for an “off the shelf” therapyNick Cernese - EY
Peter Emtage - Kite Pharma Inc
Pascal Touchon - Atara Biotherapeutics
Stefan Wildt - Takeda Pharmaceuticals
9:50 AM - 10:20 AM (EDT)
OCTSHEADLINE KEYNOTE: Unlocking the power of data and technology to deliver on the promise of cell and gene therapiesAdlai Goldberg - EY
David Rhew - Microsoft
Orlando Serani - Johnson & Johnson
Sarah Dye - Optum
10:35 AM - 10:55 AM (EDT)
Clinical & CommercializationPRESENTATION: Clinical use of CAR-T for DLBCLDavid Miklos - Stanford University
Natural Killer CellsPRESENTATION:Natural Killer cells in cancer immunotherapyJeffrey S Miller - University of Minnesota Medical School
Vein to VeinPRESENTATION:Transitioning from outsourcing to in-house manufacturing facilities and accessing cell therapy manufacturing modelsKnut Niss - Mustang Bio
CAR-T R&DPRESENTATION: Cartitude-1 Study with Updates in Toxicity & ManagementDeepu Madduri - The Mount Sinai Hospital
11:00 AM - 11:20 AM (EDT)
Clinical & CommercializationPRESENTATION: Non-viral technologies for development and manufacture of next generation cell therapiesShirley O'Dea - Avectas
CAR-T R&DPRESENTATION: Technology (and) Innovation to support the global scaleup challenges on the horizon:Steven Lynum - PHC Corporation
Carl Radosevich - PHC Corporation
11:35 AM - 11:55 AM (EDT)
Vein to VeinPRESENTATION: Guidelines for cell characterisation and cell functionJohn Elliot - NIST
Clinical & CommercializationPRESENTATION: Large B cell lymphoma long term safety trialsCaron Jacobson - Dana Faber Cancer Institute
Natural Killer CellsPRESENTATION: Maximising the therapeutic effect of allogeneic natural killer cellsJames Trager - Nkarta
Ivan Chan - Nkarta
CAR-T R&DPRESENTATION: Using Red Cell Therapeutics to Enhance Antitumor Immune ReponsesChristina Coughlin - Rubius Therapeutic
12:00 PM - 12:20 PM (EDT)
OCTSPRESENTATION: Scale-Out of Commercially Viable Autologous CAR T Cell Manufacturing Fred Koller - Miltenyi Biotec, Inc.
Track Name Speakers
8:55 AM - 9:15 AM (EDT)
OCTSPRESENTATION: Development of autologous cellular immunotherapies optimizing personalized, tumor directer TILsMaria Fardis - Iovance Biotherapeutics
9:30 AM - 9:50 AM (EDT)
Clinical & CommercializationPRESENTATION: Development of TCR T cell Therapies for Treatment of Solid TumorsPaul Stead - Adaptimmune
Vein to VeinPRESENTATION: CMC project management for cell and gene therpaiesSeshu Tyagarajan - Novartis Pharmaceuticals Corporation
Rachit Jain - Werum IT Solutions America
CAR-T R&DPRESENTATION: Enhancing CAR-T with small molecules to regulate for enhanced activity against solid tumorSteve Shamah - Obsidian Therapeutics
9:55 AM - 10:15 AM (EDT)
Vein to VeinPRESENTATION: Next Generation Workforce Development for Cell Therapy ManufacturingHaro Hartounian - BioPharma Innovation
Clinical & CommercializationPRESENTATION: Artificial intelligence for tumor specific neoantigen identificationMatt Davis - Gritstone Oncology
10:20 AM - 10:50 AM (EDT)
Clinical & CommercializationPRESENTATION: Lentiviral vectors: towards more cost-effective, scalable and regulatory-compliance processes.Juan Carlos Ramirez - VIVEbiotech
CAR-T R&DPRESENTATION: Molecular Characterization for CAR-T Cell Therapy: A Step Toward Standardization with the nCounter® CAR-T Characterization PanelErin Piazza - NanoString
10:55 AM - 11:20 AM (EDT)
OCTSInteractive Focused Round Tables 2: Development of Functional Lymphocytes from Human Pluripotent Stem CellsDan Kaufman - UCSD
OCTSInteractive Focused Round Tables 1: Cell Homing to Target Solid TumorsRobert Kochl - Kings College London
OCTSInteractive Focused Round Tables 3: Targeting glioblastoma through the use of cell therapiesAndrew Spiegel - Global Colon Cancer Association
11:25 AM - 11:45 AM (EDT)
CAR-T R&DPRESENTATION: Fusion Proteins to bridge CAR19 T cell and tumor cellsPaul Rennert - Aleta Biotherapeutics
11:50 AM - 12:10 PM (EDT)
OCTSPRESENTATION: Vd1 Gammadelta T CellsAlice Brown - GammaDelta Therapeutics
Track Name Speakers
9:05 AM - 9:40 AM (EDT)
OCTSPRESENTATION: Challenges of Vector Production in Support of Phase I Clinical TrialsSteven Feldman - Stanford Center for Cancer Cell Therapy
9:45 AM - 10:20 AM (EDT)
OCTSPRESENTATION: Best practice REMS developmentLarissa Lapteva - FDA
10:25 AM - 10:45 AM (EDT)
OCTSPRESENTATION: Adoptive cell therapy using engineered TAC T-cells to invade solid tumorsPaul Lammers - Triumvira Immunologics
10:50 AM - 11:10 AM (EDT)
OCTSPRESENTATION: TRuC®-T Cells: Harnessing The Full T Cell Receptor without HLA Restriction for Cancer TherapyRobert Hofmeister - TCR2
11:25 AM - 11:45 AM (EDT)
OCTSPRESENTATION: Digital Solution for Cell and Gene Therapy with Lessons learnedRyan Hamilton - Werum IT
Rachit Jain - Werum IT Solutions America
11:50 AM - 12:20 PM (EDT)
OCTSPANEL: Allogeneic TherapiesPeggy Sotiropoulou - Celyad Oncology
Alan Trounson - Cartherics Pty Ltd
1:00 PM - 6:00 PM (EDT)
OCTSDedicated Networking Time - until 6:30pm